Stefan Dove

Find an error

Name:
Organization: University of Regensburg , Germany
Department: Institute of Pharmacy
Title: (PhD)
Co-reporter:Stephan Braun, Alexander Botzki, Sunnhild Salmen, Christian Textor, Günther Bernhardt, Stefan Dove, Armin Buschauer
European Journal of Medicinal Chemistry 2011 Volume 46(Issue 9) pp:4419-4429
Publication Date(Web):September 2011
DOI:10.1016/j.ejmech.2011.07.014
Bacterial hyaluronan lyases (Hyal) degrade hyaluronan, an important component of the extracellular matrix, and are involved in microbial spread. Hyal inhibitors may serve as tools to study the role of the enzyme, its substrates and products in the course of bacterial infections. Moreover, such enzyme inhibitors are potential candidates for antibacterial combination therapy. Based on crystal structures of Streptococcus pneumoniae Hyal in complex with a hexasaccharide substrate and with different inhibitors, 1-acylated benzimidazole-2-thiones and benzoxazole-2-thiones were derived as new leads for the inhibition of Streptococcus agalactiae strain 4755 Hyal. Structure-based optimization led to N-(3-phenylpropionyl)benzoxazole-2-thione, one of the most potent compounds known to date (IC50 values: 24 μM at pH 7.4, 15 μM at pH 5). Among the 27 new derivatives, other N-acylated benzimidazoles and benzoxazoles are just as active at pH 7.4, but not at pH 5. The results support a binding mode characterized by interactions with residues in the catalytic site and with a hydrophobic patch.Highlights► We derived new leads for inhibition of streptococcal hyaluronan lyases. ► Hyaluronan lyase–ligand complexes were used for structure-based design. ► As result, we analyzed 1-acylated benzimidazole-2-thiones and benzoxazole-2-thiones. ► N-(3-Phenylpropionyl)benzoxazole-2-thione was the most potent SagHyal inhibitor. ► The structure–activity relationships correspond to the suggested binding mode.
Co-reporter:Maria Elena Silva;Ralf Heim;Andrea Strasser
Journal of Computer-Aided Molecular Design 2011 Volume 25( Issue 1) pp:51-66
Publication Date(Web):2011 January
DOI:10.1007/s10822-010-9400-2
A series of 51 5-HT2A partial agonistic arylethylamines (primary or benzylamines) from different structural classes (indoles, methoxybenzenes, quinazolinediones) was investigated by fragment regression analysis (FRA), docking and 3D-QSAR approaches. The data, pEC50 values and intrinsic activities (Emax) on rat arteries, show high variability of pEC50 from 4 to 10 and of Emax from 15 to 70%. FRA indicates which substructures affect potency or intrinsic activity. The high contribution of halogens in para position of phenethylamines to pEC50 points to a specific hydrophobic pocket. Other results suggest the significance of hydrogen bonds of the aryl moiety for activation and the contrary effect of benzyl groups on affinity (increasing) and intrinsic activity (decreasing). Results from fragment regression and data on all available mutants were considered to derive a common binding site at the rat 5-HT2A receptor. After generation and MD simulations of a receptor model based on the β2-adrenoceptor structure, typical derivatives were docked, leading to the suggestion of common interactions, e.g., with serines in TM3 and TM5 and with a cluster of aromatic amino acids in TM5 and TM6. The whole series was aligned by docking and minimization of the complexes. The pEC50 values correlate well with Sybyl docking energies and hydrophobicity of the aryl moieties. With this alignment, CoMFA and CoMSIA approaches based on a training set of 36 and a test set of 15 compounds were performed. The correlation of pEC50 with steric, electrostatic, hydrophobic and H-bond acceptor fields resulted in sufficient fit (q2: 0.75–0.8, r2: 0.92–0.95) and predictive power (rpred2: 0.85–0.88). The important interaction regions largely reflect the patterns provided by the putative binding site. In particular, the fit of the aryl moieties and benzyl substituents to two hydrophobic pockets is evident.
Co-reporter:Stefan Dove
Archiv der Pharmazie 2004 Volume 337(Issue 12) pp:
Publication Date(Web):13 DEC 2004
DOI:10.1002/ardp.200400619

Dopamine β-monooxygenase (DBM, EC 1.14.17.1) catalyzes the oxidation of dopamine into (R)-noradrenaline. DBM inhibitors may act as antihypertensive drugs. A series of 22 picolinic acids substituted in 4- and 5-position was previously synthesized and tested for inhibition of DBM from bovine adrenal medulla. The QSAR of these compounds were investigated by Hansch analysis and comparative molecular field analysis (CoMFA). The correlation of pI50 values with electronic (nucleophilic substituent constant σp, oxygen net charges and highest occupied molecular orbital energy calculated by AMPAC-AM1), hydrophobic (π values of R4) and steric descriptors (molar refraction and Sterimol parameters of R5) indicated that a more negatively charged carboxylate moiety, more lipophilic R4 groups as well as wider bulk and higher molar refraction of 5-substituents increase DBM inhibition. The CoMFA approach generally reproduced these QSAR in terms of steric and electrostatic field variables, the latter restricted to the carboxylate area. To predict a putative binding site, dopamine and fusaric acid were docked into a partial homology model of DBM derived from a crystal structure of peptidylglycine α-hydroxylating monooxygenase (EC 1.14.17.3). The inhibitor is suggested to interact by its carboxylate group with the copper site CuB and the protonated amino group of dopamine according to the uncompetitive type of inhibition. R4 points to a tyrosine side chain. R5 protrudes into the fringe of the catalytic crevice. It may “freeze” to the solvated surface of polar amino acids and additionally contact an isoleucine residue. Taken together, the model explains the QSAR results by corresponding types of interaction.

6-Chloro-1-(phenylsulfonyl)-1H-indole
1H-Imidazole-4-ethanamine, N,1-bis(triphenylmethyl)-
2-Furanmethanamine, tetrahydro-5-(1H-imidazol-4-yl)-, (2S,5R)-
2-Furanmethanamine, tetrahydro-5-(1H-imidazol-4-yl)-, (2R,5S)-
2,5(1H,3H)-Quinazolinedione,4-(3,4-dichlorophenyl)-4,6,7,8-tetrahydro-
2,5(1H,3H)-Quinazolinedione,4-(2,4-dichlorophenyl)-4,6,7,8-tetrahydro-
2,5(1H,3H)-Quinazolinedione, 4-(2-fluorophenyl)-4,6,7,8-tetrahydro-
Benzoic acid,4-[[[2-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]amino]carbonyl]-,methyl ester
4-(4-METHYLPHENYL)-1,3,4,6,7,8-HEXAHYDROQUINAZOLINE-2,5-DIONE